Advertisement

Psychopharmacology

, Volume 234, Issue 7, pp 1121–1134 | Cite as

The effects of synthetic cannabinoids on executive function

  • K Cohen
  • M Kapitány-Fövény
  • Y Mama
  • M Arieli
  • P Rosca
  • Z Demetrovics
  • A WeinsteinEmail author
Original Investigation

Abstract

Background and aims

There is a growing use of novel psychoactive substances (NPSs) including synthetic cannabinoids. Synthetic cannabinoid products have effects similar to those of natural cannabis but the new synthetic cannabinoids are more potent and dangerous and their use has resulted in various adverse effects. The purpose of the study was to assess whether persistent use of synthetic cannabinoids is associating with impairments of executive function in chronic users.

Methods

A total of 38 synthetic cannabinoids users, 43 recreational cannabis users, and 41 non-user subjects were studied in two centers in Hungary and Israel. Computerized cognitive function tests, the classical Stroop word-color task, n-back task, and a free-recall memory task were used.

Results

Synthetic cannabinoid users performed significantly worse than both recreational and non-cannabis users on the n-back task (less accuracy), the Stroop task (overall slow responses and less accuracy), and the long-term memory task (less word recall). Additionally, they have also shown higher ratings of depression and anxiety compared with both recreational and non-users groups.

Discussion

This study showed impairment of executive function in synthetic cannabinoid users compared with recreational users of cannabis and non-users. This may have major implications for our understanding of the long-term consequences of synthetic cannabinoid based drugs.

Keywords

Synthetic cannabinoids Cannabis Working memory Control inhibition Long-term memory 

Notes

Acknowledgements

This study was partly funded by a grant from the National Institute for Psychobiology in Israel to Prof. Weinstein. The study was published as an M.A. thesis for Koby Cohen. We would like to thank the managers of the treatment centers of the Ministry of Health in Israel (Ashdod, Lifta, Haderech, Tamra, and Malcishua) and in Hungary for allowing access to patients. The study was presented at the fourth meeting on Novel Psychoactive Substances in Budapest 31 March 2016 and the 78th meeting of the College on Problems of Drug Dependence in Palms Springs CA USA in 11–16 June 2016.

References

  1. Aharonovich E, Brooks AC, Nunes EV, Hasin DS (2008) Cognitive deficits in marijuana users: effects on motivational enhancement therapy plus cognitive behavioral therapy treatment outcome. Drug Alcohol Depend 95(3):279–283CrossRefPubMedPubMedCentralGoogle Scholar
  2. Akirav I (2011) The role of cannabinoids in modulating emotional and non-emotional memory processes in the hippocampus. Front Behav Neurosci 5(34):34–47PubMedPubMedCentralGoogle Scholar
  3. Arguello PA, Jentsch JD (2004) Cannabinoid CB1 receptor-mediated impairment of visuospatial attention in the rat. Psychopharmacology 177(1):141–150CrossRefPubMedGoogle Scholar
  4. Basavarajappa BS, Subbanna S (2014) CB1 receptor-mediated signaling underlies the hippocampal synaptic, learning, and memory deficits following treatment with JWH-081, a new component of spice/K2 preparations. Hippocampus 24(2):178–88Google Scholar
  5. Bates ME, Pawlak AP, Tonigan JS, Buckman JF (2006) Cognitive impairment influences drinking outcome by altering therapeutic mechanisms of change. Psychol Addict Behav 20(3):241CrossRefPubMedPubMedCentralGoogle Scholar
  6. Beck AT, Ward C, Mendelson M (1961) Beck depression inventory (BDI). Arch Gen Psychiatry 4(6):561–571CrossRefPubMedGoogle Scholar
  7. Beck AT, Steer RA, Garbin MG (1988) Psychometric properties of the Beck depression inventory: twenty-five years of evaluation. Clin Psychol Rev 8(1):77–100CrossRefGoogle Scholar
  8. Block RI, O’Leary DS, Hichwa RD, Augustinack JC, Ponto LLB, Ghoneim MM, Hall JA (2002) Effects of frequent marijuana use on memory-related regional cerebral blood flow. Pharmacol Biochem Behav 72(1):237–250CrossRefPubMedGoogle Scholar
  9. Bossong GM, Jager G, Bhattacharyya S, Allen P (2014) Acute and non-acute effects of cannabis on human memory function: a critical review of neuroimaging studies. Curr Pharm Des 20(13):2114–2125CrossRefPubMedGoogle Scholar
  10. Budney AJ, Hughes JR, Moore BA, Vandrey R (2004) Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 161(11):1967–1977CrossRefPubMedGoogle Scholar
  11. Buschke H (1973) Selective reminding for analysis of memory and learning. J Verbal Learn Verbal Behav 12(5):543–550CrossRefGoogle Scholar
  12. Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA (2014) Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 144:12–41CrossRefPubMedGoogle Scholar
  13. Castellanos D, Thornton G (2012) Synthetic cannabinoid use: recognition and management. J Psychiatr Pract 18(2):86–93CrossRefPubMedGoogle Scholar
  14. Castellanos D, Singh S, Thornton G, Avila M, Moreno A (2011) Synthetic cannabinoid use: a case series of adolescents. J Adolesc Health 49(4):347–349CrossRefPubMedGoogle Scholar
  15. Colom R, Román FJ, Abad FJ, Shih PC, Privado J, Froufe M et al (2013) Adaptive n-back training does not improve fluid intelligence at the construct level: gains on individual tests suggest that training may enhance visuospatial processing. Intelligence 41(5):712–727CrossRefGoogle Scholar
  16. Crean RD, Crane NA, Mason BJ (2011) An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. Journal of Addiction Medicine 5(1):1–8CrossRefPubMedPubMedCentralGoogle Scholar
  17. Curran VH, Brignell C, Fletcher S, Middleton P, Henry J (2002) Cognitive and subjective dose-response effects of acute oral Δ9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology 164(1):61–70CrossRefPubMedGoogle Scholar
  18. Diamond A (2013) Executive functions. Annu Rev Psychol 64:135–168CrossRefPubMedGoogle Scholar
  19. Egerton A, Allison C, Brett RR, Pratt JA (2006) Cannabinoids and prefrontal cortical function: insights from preclinical studies. Neurosci Biobehav Rev 30(5):680–695CrossRefPubMedGoogle Scholar
  20. Eldreth DA, Matochik JA, Cadet JL, Bolla KI (2004) Abnormal brain activity in prefrontal brain regions in abstinent marijuana users. NeuroImage 23(3):914–920CrossRefPubMedGoogle Scholar
  21. Fattore L, Fratta W (2011) Beyond THC: the new generation of cannabinoid designer drugs. Front Behav Neurosci 5(60):1–12Google Scholar
  22. Filbey FM, McQueeny T, Kadamangudi S, Bice C, Ketcherside A (2015) Combined effects of marijuana and nicotine on memory performance and hippocampal volume. Behav Brain Res 293:46–53CrossRefPubMedPubMedCentralGoogle Scholar
  23. Friedman NP, Miyake A, Corley RP, Young SE, DeFries JC, Hewitt JK (2006) Not all executive functions are related to intelligence. Psychol Sci 17(2):172–179CrossRefPubMedGoogle Scholar
  24. Funahashi S (2001) Neuronal mechanisms of executive control by the prefrontal cortex. Neurosci Res 39(2):147–165CrossRefPubMedGoogle Scholar
  25. Ghitza UE, Epstein DH, Schmittner J, Vahabzadeh M, Lin JL, Preston KL (2007) Randomized trial of prize-based reinforcement density for simultaneous abstinence from cocaine and heroin. J Consult Clin Psychol 75(5):765–744CrossRefPubMedPubMedCentralGoogle Scholar
  26. Goldman-Rakic PS (1995) Architecture of the prefrontal cortex and the central executive. Ann N Y Acad Sci 769:71–83CrossRefPubMedGoogle Scholar
  27. Gottschalk C, Beauvais J, Hart R, Kosten T (2001) Cognitive function and cerebral perfusion during cocaine abstinence. Am J Psychiatr 158(4):540–545CrossRefPubMedGoogle Scholar
  28. Hackman DA, Farah MJ (2009) Socioeconomic status and the developing brain. Trends Cogn Sci 13(2):65–73CrossRefPubMedPubMedCentralGoogle Scholar
  29. Harris CR, Brown A (2013) Synthetic cannabinoid intoxication: a case series and review. The Journal of Emergency Medicine 44(2):360–366CrossRefPubMedGoogle Scholar
  30. Hatchard T, Fried PA, Hogan MJ, Cameron I, Smith AM (2014) Marijuana use impacts cognitive interference: an fMRI investigation in young adults performing the counting Stroop task. Journal of Addiction Research & Therapy 5(4):197–203CrossRefGoogle Scholar
  31. Hermanns-Clausen M, Kneisel S, Szabo B, Auwärter V (2013) Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 108(3):534–544CrossRefPubMedGoogle Scholar
  32. Hester R, Nestor L, Garavan H (2009) Impaired error awareness and anterior cingulate cortex hypoactivity in chronic cannabis users. Neuropsychopharmacology 34(11):2450–2458CrossRefPubMedPubMedCentralGoogle Scholar
  33. Hill MN, Froc DJ, Fox CJ, Gorzalka BB, Christie BR (2004) Prolonged cannabinoid treatment results in spatial working memory deficits and impaired long-term potentiation in the CA1 region of the hippocampus in vivo. Eur J Neurosci 20(3):859–863CrossRefPubMedGoogle Scholar
  34. Jaeggi SM, Buschkuehl M, Perrig WJ, Meier B (2010) The concurrent validity of the N-back task as a working memory measure. Memory 18(4):394–412CrossRefPubMedGoogle Scholar
  35. Jager G, Kahn RS, Van Den Brink W, Van Ree JM, Ramsey NF (2006) Long-term effects of frequent cannabis use on working memory and attention: an fMRI study. Psychopharmacology 185(3):358–368CrossRefPubMedGoogle Scholar
  36. Jager G, Van Hell HH, De Win MML, Kahn RS, Van Den Brink W, Van Ree JM, Ramsey NF (2007) Effects of frequent cannabis use on hippocampal activity during an associative memory task. Eur Neuropsychopharmacol 17(4):289–297CrossRefPubMedGoogle Scholar
  37. Julian LJ (2011) Measures of anxiety: state-trait anxiety inventory (STAI), Beck anxiety inventory (BAI), and hospital anxiety and depression scale-anxiety (HADS-A). Arthritis Care & Research 63(S11):S467–S472 JOURCrossRefGoogle Scholar
  38. Kanayama G, Rogowska J, Pope HG, Gruber SA, Yurgelun-Todd DA (2004) Spatial working memory in heavy cannabis users: a functional magnetic resonance imaging study. Psychopharmacology 176(3):239–247CrossRefPubMedGoogle Scholar
  39. Kopp MS, Skrabski Á, Szedmák S (1995) Socioeconomic factors, severity of depressive symptomatology, and sickness absence rate in the Hungarian population. J Psychosom Res 39(8):1019–1029CrossRefPubMedGoogle Scholar
  40. Lichtman AH, Varvel SA, Martin BR (2002) Endocannabinoids in cognition and dependence. Prostaglandins Leukot Essent Fat Acids 66(2):269–285CrossRefGoogle Scholar
  41. Macfarlane V, Christie G (2015) Synthetic cannabinoid withdrawal: a new demand on detoxification services. Drug Alcohol Rev 34(2):147–153CrossRefPubMedGoogle Scholar
  42. Maćkowiak M, Chocyk A, Dudys D, Wedzony K (2009) Activation of CB1 cannabinoid receptors impairs memory consolidation and hippocampal polysialylated neural cell adhesion molecule expression in contextual fear conditioning. Neuroscience 158(4):1708–1716CrossRefPubMedGoogle Scholar
  43. MacLeod CM (1991) Half a century of research on the Stroop effect: an integrative review. Psychol Bull 109(2):163–203CrossRefPubMedGoogle Scholar
  44. Miller KM, Price CC, Okun MS, Montijo H, Bowers D (2009) Is the n-back task a valid neuropsychological measure for assessing working memory? Arch Clin Neuropsychol 24(7):711–717CrossRefPubMedPubMedCentralGoogle Scholar
  45. Miller RLA, Thakur GA, Stewart WN, Bow JP, Bajaj S, Makriyannis A, McLaughlin PJ (2013) Effects of a novel CB1 agonist on visual attention in male rats: role of strategy and expectancy in task accuracy. Exp Clin Psychopharmacol 21(5):416–425CrossRefPubMedPubMedCentralGoogle Scholar
  46. Misner DL, Sullivan JM (1999) Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons. J Neurosci 19(16):6795–6805PubMedGoogle Scholar
  47. Nacca N, Vatti D, Sullivan R, Sud P, Su M, Marraffa J (2013) The synthetic cannabinoid withdrawal syndrome. Journal of Addiction Medicine 7(4):296–298CrossRefPubMedGoogle Scholar
  48. Nava F, Carta G, Battasi AM, Gessa GL (2000) D2 dopamine receptors enable Δ9-tetrahydrocannabinol induced memory impairment and reduction of hippocampal extracellular acetylcholine concentration. Br J Pharmacol 130(6):1201–1210CrossRefPubMedPubMedCentralGoogle Scholar
  49. Oluwabusi OO, Lobach L, Akhtar U, Youngman B, Ambrosini PJ (2012) Synthetic cannabinoid-induced psychosis: two adolescent cases. Journal of Child and Adolescent Psychopharmacology 22(5):393–395CrossRefPubMedGoogle Scholar
  50. Pattij T, Wiskerke J, Schoffelmeer ANM (2008) Cannabinoid modulation of executive functions. Eur J Pharmacol 585(2):458–463CrossRefPubMedGoogle Scholar
  51. Pistis M, Ferraro L, Pira L, Flore G, Tanganelli S, Gessa GL, Devoto P (2002) Δ 9-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res 948(1):155–158CrossRefPubMedGoogle Scholar
  52. Renard J, Krebs MO, Le Pen G, & Jay, TM (2014) Long-term consequences of adolescent cannabinoid exposure in adult psychopathology. Frontiers in Neuroscience 8:361. doi: 10.3389/fnins.2014.00361
  53. Reyes BAS, Rosario JC, Piana PMT, Van Bockstaele EJ (2009) Cannabinoid modulation of cortical adrenergic receptors and transporters. J Neurosci Res 87(16):3671–3678CrossRefPubMedPubMedCentralGoogle Scholar
  54. Robbins TW, Arnsten AFT (2009) The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. Annu Rev Neurosci 32:267–287CrossRefPubMedPubMedCentralGoogle Scholar
  55. Robinson L, Goonawardena AV, Pertwee RG, Hampson RE, Riedel G (2007) The synthetic cannabinoid HU210 induces spatial memory deficits and suppresses hippocampal firing rate in rats. Br J Pharmacol 151(5):688–700CrossRefPubMedPubMedCentralGoogle Scholar
  56. Rosenbaum M, Najenson T (1976) Changes in life patterns and symptoms of low mood as reported by wives of severely brain-injured soldiers. J Consult Clin Psychol 44(6):861–881CrossRefGoogle Scholar
  57. Seely KA, Lapoint J, Moran JH, Fattore L (2012) Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuro-Psychopharmacol Biol Psychiatry 39(2):234–243CrossRefGoogle Scholar
  58. Sipos K, Sipos M (1983) The development and validation of the Hungarian form of the state-trait anxiety inventory. Series in Clinical & Community Psychology: Stress & Anxiety 2:27–39Google Scholar
  59. Smith AM, Longo CA, Fried PA, Hogan MJ, Cameron I (2010) Effects of marijuana on visuospatial working memory: an fMRI study in young adults. Psychopharmacology 210(3):429–438CrossRefPubMedGoogle Scholar
  60. Soussan C, Kjellgren A (2014) The flip side of “spice”: the adverse effects of synthetic cannabinoids as discussed on a Swedish Internet forum. Nordic Stud Alcohol Drugs 31(2):207–220CrossRefGoogle Scholar
  61. Spaderna M, Addy PH, D’Souza DC (2013) Spicing things up: synthetic cannabinoids. Psychopharmacology 228(4):525–540CrossRefPubMedPubMedCentralGoogle Scholar
  62. Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA (1983) Manual for the state-trait anxiety inventory. Manual for the state-trait anxiety inventory. Consulting Psychologists Press, Palo AltoGoogle Scholar
  63. Török S, Kökönyei G, Károlyi L, Ittzés A, Tomcsányi T (2006) Outcome effectiveness of therapeutic recreation camping program for adolescents living with cancer and diabetes. J Adolesc Health 39(3):445–447CrossRefPubMedGoogle Scholar
  64. Van der Stelt M, Di Marzo V (2003) The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol 480(1):133–150CrossRefPubMedGoogle Scholar
  65. Vandrey R, Dunn KE, Fry JA, Girling ER (2012) A survey study to characterize use of spice products (synthetic cannabinoids). Drug Alcohol Depend 120(1):238–241CrossRefPubMedGoogle Scholar
  66. Winstock AR, Barratt MJ (2013) Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend 131(1):106–111CrossRefPubMedGoogle Scholar
  67. Yeakel JK, Logan BK (2013) Blood synthetic cannabinoid concentrations in cases of suspected impaired driving. J Anal Toxicol 37(8):547–551CrossRefPubMedGoogle Scholar
  68. Zawilska JB (2011) Legal highs: new players in the old drama. Current Drug Abuse Reviews 4(2):122–130CrossRefPubMedGoogle Scholar
  69. Zimmermann US, Winkelmann PR, Pilhatsch M, Nees JA, Spanagel R, Schulz K (2009) Withdrawal phenomena and dependence syndrome after the consumption of “spice gold”. Dtsch Arztebl Int 106(27):464–467PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • K Cohen
    • 1
    • 2
  • M Kapitány-Fövény
    • 2
    • 3
    • 4
  • Y Mama
    • 1
  • M Arieli
    • 5
  • P Rosca
    • 6
  • Z Demetrovics
    • 2
  • A Weinstein
    • 1
    Email author
  1. 1.Department of Behavioral Science and Integrative Brain and Cognition CenterUniversity of ArielArielIsrael
  2. 2.Institute of PsychologyEötvös Loránd UniversityBudapestHungary
  3. 3.Faculty of Health SciencesSemmelweis UniversityBudapestHungary
  4. 4.Nyírő Gyula HospitalNational Institute of Psychiatry and Addictions BudapestBudapestHungary
  5. 5.Division of Enforcement and InspectionMinistry of HealthJerusalemIsrael
  6. 6.Department for the Treatment of Substance AbuseMinistry of HealthJerusalemIsrael

Personalised recommendations